Rechercher des projets européens

31 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Translating neuroimaging findings from research into clinical practice (PSYSCAN)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2020,

Abstract 9Neuroimaging (NI) has enormous potential to improve the clinical care of patients with psychiatric disorders, but has yet to deliver. The PSYSCAN project will address this issue directly by developing a NI-based tool that will help clinicians resolve key clinical issues in the management of patients with psychotic disorders. Clinicians will use the tool to assess patients with a standard ...
Voir le projet

 24

 TERMINÉ 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

...ty for AD prevention trials with limited clinical background is both a risky and cost-inefficient strategy. Creating a disease register of people consented to enter secondary prevention trials delivers a degree of readiness that ensures better knowledge of a participants suitability and a more rapid throughput of screening for the trials. The EPAD Consortium has the necessary reach and influence f ...
Voir le projet

 40

 TERMINÉ 

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Voir le projet

 34

 TERMINÉ 

Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT)

Date du début: 1 juil. 2014, Date de fin: 30 juin 2019,

...armaceutical investigations; (5) identification of biomarkers and health technology solutions to be implemented into clinical practice. Thus, the project is expected to pursue all the research deliverables described in nine work-packages.The SPRINTT project proposes a novel operationalisation of physical frailty recognising sarcopenia as its central biological substrate. This approach is based on ...
Voir le projet

 27

 TERMINÉ 

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases (PRECISESADS)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

...), Sjögren’s syndrome (Sjs), rheumatoid arthritis (RA), primary antiphospholipid syndrome (PAPS) and mixed connective tissue disease (MCTD), jointly as systemic autoimmune diseases (SADs). We believe that there will be overlapping clusters of individuals across diseases that will share molecular features. To determine these clusters we will, study 2000 cases of SADs, and 600 healthy controls to id ...
Voir le projet

 30

 TERMINÉ 

DIabetes REsearCh on patient sTratification (DIRECT)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2019,

The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies.There is heterogeneity in who develops diabetes, the rate at which th ...
Voir le projet

 27

 TERMINÉ 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

...lligent environmental testing of pharmaceuticals in development and to prioritise legacy pharmaceuticals for full environmental risk assessment and/or environmental (bio) monitoring. The aim will be delivered through a number of specific objectives: 1) to review existing approaches for prioritisation and mode of action based intelligent testing of APIs and develop improved frameworks; 2) to establ ...
Voir le projet

 29

 TERMINÉ 

REgeneration of inner ear hair cells with GAmma-secretase INhibitors to regain hearing in patients with sensorineural hearing loss (REGAIN)

Date du début: 1 mai 2015, Date de fin: 31 oct. 2018,

Hearing loss is a chronic non-communicable disease disabling over 328 million adults, and 32 million children worldwide. Sensorineural hearing loss due to loss of auditory hair cells was long thought to be irreversible. However, recent animal studies have demonstrated that pharmacological inhibition of cell signalling via Notch receptors using gamma-secretase inhibitors (GSIs) can regenerate hair ...
Voir le projet

 7

 TERMINÉ 

Diagnostic and Drug Discovery Initiative for Alzheimer’s Disease (D3i4AD)

Date du début: 1 oct. 2014, Date de fin: 30 sept. 2018,

...ich has no cure at the moment. The overall aim of the work described in this proposal is to create a long-term strategic partnership between Sheffield University (UK), Lisbon University (Portugal), Eli Lilly (UK) and Biofordrug (Italy) in order to develop chemical biology tools for better understanding the role of PrPC in AD and harnessing this understanding to develop novel chemical entities for ...
Voir le projet

 5

 TERMINÉ 

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Date du début: 1 sept. 2011, Date de fin: 31 déc. 2017,

... consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision-making in Phase ...
Voir le projet

 26

 TERMINÉ 

Delivering European Translational Information & Knowledge Management Services (ETRIKS)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

...sary overheads and a substantial risk to the legacy of datasets. The end result is a less than full realization of the potential of IMI to diminish bottlenecks in drug and diagnostic development. ’Delivering eTRIKS’ will address this gap by providing a sustainable, open IMI translational research informatics/KM platform – eTRIKS, and delivering associated support, expertise and services. Developme ...
Voir le projet

 17

 TERMINÉ 

Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) (STEMBANCC)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Voir le projet

 38

 TERMINÉ 

European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)

Date du début: 1 avr. 2012, Date de fin: 31 mars 2017,

...of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories which provide a collection of biologically heterogeneous patients. Further, even if novel treatments are developed there is no EU platform to clinic ...
Voir le projet

 29

 TERMINÉ 

European Patients' Academy on Therapeutic Innovation (EUPATI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

...cademy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocates and advisors, e.g. in pharmaceutical deve ...
Voir le projet

 33

 TERMINÉ 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Voir le projet

 29

 TERMINÉ 

European Bank for induced pluripotent Stem Cells (EBISC)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Voir le projet

 30

 TERMINÉ 

OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Voir le projet

 22

 TERMINÉ 

Incorporating real-life clinical data into drug development (GETREAL)

Date du début: 1 oct. 2013, Date de fin: 31 déc. 2016,

...t uncertainty relating to the reimbursement, and thus market implementation of new medication once approved by regulatory authorities, is negatively affecting the value of the drug development pipeline. The costly clinical developments to get to market approval, no longer seem to be a guarantee for market entry. This new risk presents a serious additional hurdle for drug developers that already fa ...
Voir le projet

 32

 TERMINÉ 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet

 34

 TERMINÉ 

Drug Disease Model Resources (DDMORE)

Date du début: 1 mars 2011, Date de fin: 31 août 2016,

Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Voir le projet

 28

 TERMINÉ 

European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)

Date du début: 1 sept. 2009, Date de fin: 30 juin 2016,

...lona, the Erasmus University Medical Center, the University of Utrecht, the University of Hert[ordshire, the University of Verona, the Karolinska Institute and the European Medicines Agency. It will deliver programmes in harmacovigilance and Pharmacoepidemiology for continuing education diploma, Master’s degree as well as PhD and a short course orientated towards risk communication. Targetedaudien ...
Voir le projet

 24

 TERMINÉ 

The Open Pharmacological Concepts Triple Store (OPEN PHACTS)

Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,

Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, requiring shared identifiers and common semantics. Expression profiles need to be overlaid with gene or pathway identifiers an ...
Voir le projet

 32

 TERMINÉ 

Electronic Health Record systems for Clinical Research (EHR4CR)

Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,

Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical ...
Voir le projet

 37

 TERMINÉ 

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Voir le projet

 38

 TERMINÉ 

Pharmacogenomic biomarkers as clinical decision making tools for clozapine treatment of schizophrenia (CRESTAR)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

Treatment resistant schizophrenia (TRS) is the most disabling of all psychiatric illnesses, affecting about 1/3 of patients (~1 million Europeans), a considerable economic and social burden. First-line treatments include atypical (e.g. olanzapine) and typical (e.g. haloperidol) antipsychotics. The original atypical, clozapine, is a final option, and although it is the only antipsychotic shown to b ...
Voir le projet

 11

 TERMINÉ 

SUrrogate markers for vascular Micro- and Macrovascular hard endpoints for Innovative diabetes Tools (SUMMIT)

Date du début: 1 nov. 2009, Date de fin: 31 oct. 2015,

Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can neither be prevented nor cured and the disease is associated with devastating chronic complications including coronary heart disease and stroke (macrovascular disease) as we ...
Voir le projet

 27

 TERMINÉ 

Understanding chronic pain and improving its treatment (EUROPAIN)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2015,

...and mutually supportive programs of experimental research, underpinned and supported by a coordinated training and bioinformatics facility. These programs will form a series of workpackages each delivered through collaboration of network laboratories to bring together multiple techniques and considerable expertise to each area. In addition, there will be considerable synergies between the programs ...
Voir le projet

 29

 TERMINÉ 

Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes (IMIDIA)

Date du début: 1 févr. 2010, Date de fin: 30 sept. 2015,

...onsortium of leading European experts from universities and SMEs in the fields of beta-cell diabetes research,gene transfer technology, metabolom ics, biomedical imaging, bioinformatics and systemsmodeling. We propose a work plan composed of 5 scientific work packages structured to provide high levels of interaction within the network and with EFPIA partners.A management and administration work pa ...
Voir le projet

 23

 TERMINÉ 

SAFER AND FASTER EVIDENCE-BASED TRANSLATION (SAFE-T)

Date du début: 15 juin 2009, Date de fin: 14 juin 2015,

...IcatIon of drug-Induced organ injury (DILl, DIKI and DIVI) safety BM5. SAFE-T objectives will be achieved through innovative biomarkerapproaches employing leading BM technologies.The consortium will deliver a validated generic qualification process for translational safety BMs that will be released for discussion to gain its acceptance as a reference guideline by stakeholders including EFPIA and h ...
Voir le projet

 26

 TERMINÉ 

Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)

Date du début: 1 sept. 2009, Date de fin: 30 avr. 2015,

Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Voir le projet

 36

 TERMINÉ 

Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)

Date du début: 1 sept. 2009, Date de fin: 28 févr. 2015,

...e of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical trials on DSM categories which provide a collection of biologically heterogeneous patients. Our broad working hypothesis is that a focus on cross-species endophenotypes, testing in hea ...
Voir le projet

 20